TRex Bio, Inc.

Research TRex Bio, Inc. (TRXB) with Bullrun company financials, valuation charts, model signals, and historical stock context.

Key Metrics

TickerTRXB
ExchangeNASDAQ
CountryUnited States
SectorHealthcare
IndustryBiotechnology
CurrencyUSD
Financial periodFY2025
RevenueUSD 0
Revenue growth-100.0%
Net income-USD 34.81M
Free cash flow-USD 41.43M

Five-year financial history

Year	Revenue	Net income	Free cash flow	Gross margin	Diluted EPS	Cash	Total debt	Equity
FY2025	USD 0	-USD 34.81M	-USD 41.43M	n/a	-1.85	USD 15.19M	USD 717.00K	-USD 92.12M
FY2024	USD 39.11M	-USD 3.14M	-USD 25.65M	n/a	-0.47	USD 47.47M	USD 696.00K	-USD 57.97M

About TRex Bio, Inc.

TRex Bio, Inc. develops immunoregulatory biologics for autoimmune and inflammatory diseases in United States and Internationally. The company operates the Deep Biology Platform, a drug discovery and design platform that integrates tissue-level insights into human biology and treg function to identify and characterize therapeutic targets, using computational mapping, which uses in silico tools and a human tissue bank and atlas of human treg gene expression to identify pathways in tissue immune regulation;

Related stock research

United States stocks United States Healthcare stocks A-Z stock index

Other Healthcare stocks

Frontage Holdings Corporation (1521.HK) Sirnaomics Ltd. (2257.HK) Aardvark Therapeutics Inc (AARD) Abeona Therapeutics Inc (ABEO) Acumen Pharmaceuticals Inc (ABOS) Absci Corp (ABSI) Arbutus Biopharma Corp (ABUS) ABVC BioPharma Inc (ABVC) Acadia Pharmaceuticals Inc (ACAD) Adicet Bio Inc (ACET) Achieve Life Sciences Inc (ACHV) Alpha Cognition Inc (ACOG)

Frequently asked questions

What does TRex Bio, Inc. do?

TRex Bio, Inc. develops immunoregulatory biologics for autoimmune and inflammatory diseases in United States and Internationally.